The effect of KRAS allelic imbalance upon therapeutic efficacy was observed in a study by Burgess and colleagues (11), in which it was demonstrated that the relative balance between mutant and wild-type (WT) KRAS alleles determined clonal fitness and sensitivity to MAPK-targeting therapeutic approaches in acute myeloid leukemias. The gene discussed is KRAS; the disease is acute myeloid leukemia.